NEW BRUNSWICK, N.J. – Dr. Jonathan H. Sherman, a specialist in neurosurgical oncology, has been named chief of Neurosurgical Oncology at Rutgers Cancer Institute, officials announced on Wednesday. Dr. Sherman …
Tag:
oncology,
-
-
MIsc. News
Cancer drug developer CG Oncology valued at $1.75 billion in strong debut
by Reutersby ReutersBy Pritam Biswas (Reuters) -Cancer drug developer CG Oncology notched up a valuation of $1.75 billion in its market debut on Thursday, after its shares jumped 52.6% at the open, …
-
New Jersey NewsPolice Blotter
New Jersey Doctor Admits Buying and Selling Oncology Medication for Profit
by DOJ Pressby DOJ PressNEWARK, N.J. – A New Jersey doctor today admitted using his medical license – and allowing other to use his medical license – to purchase prescription oncology medications under false …
-
Business News
Jubilant Therapeutics Inc. annonce le développement d’inhibiteurs de PD-L1 à petite molécule, disponibles par voie orale et pénétrant dans le cerveau, lors de la réunion annuelle 2022 de l’American Society of Clinical Oncology (ASCO) France – Français USA – English
by Your Newsby Your NewsBEDMINSTER, N.J., 3 juin 2022 — Jubilant Therapeutics Inc., une société de thérapies de précision au stade clinique qui fait progresser les petites molécules thérapeutiques pour répondre à des besoins …
-
Business News
Jubilant Therapeutics Inc. annonce le développement d’inhibiteurs de PD-L1 à petite molécule, disponibles par voie orale et pénétrant dans le cerveau, lors de la réunion annuelle 2022 de l’American Society of Clinical Oncology (ASCO) France – Français USA – English Deutschland – Deutsch
by Your Newsby Your NewsBEDMINSTER, N.J., 3 juin 2022 — Jubilant Therapeutics Inc., une société de thérapies de précision au stade clinique qui fait progresser les petites molécules thérapeutiques pour répondre à des besoins …
-
Business News
Jubilant Therapeutics Inc. berichtet auf der Jahrestagung 2022 der American Society of Clinical Oncology (ASCO) über die Entwicklung oral verfügbarer und ins Gehirn eindringender niedermolekularer PD-L1-Inhibitoren Deutschland – Deutsch USA – English France – Français
by Your Newsby Your NewsBEDMINSTER, N.J., 3. Juni 2022 — Jubilant Therapeutics Inc., ein Unternehmen für Präzisionstherapeutika in der klinischen Phase, das niedermolekulare Therapeutika für ungedeckten medizinischen Bedarf in der Onkologie und bei Autoimmunerkrankungen …
-
Business News
Taiho Oncology Announces Updated Efficacy and Safety Data for Futibatinib in Cholangiocarcinoma at 2022 ASCO Annual Meeting
by Your Newsby Your NewsThese data are part of a New Drug Application that has been granted priority review by the U.S. Food and Drug Administration PRINCETON, N.J., June 3, 2022 — Taiho Oncology, …
-
Department of Justice Press Releases
New York Doctor Admits Buying and Selling Oncology Medication for Profit
by DOJ Pressby DOJ PressNEWARK, N.J. – A New York doctor today admitted using his medical license – and allowing others to use his medical license – to purchase prescription oncology medications under false …